| dc.contributor.author | KINGSTON, WILLIAM | |
| dc.date.accessioned | 2007-02-19T19:45:01Z | |
| dc.date.available | 2007-02-19T19:45:01Z | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006 | en |
| dc.identifier.citation | William Kingston, Limited Incontestability for Small-Firm Patents, European Intellectual Property Review, 28, (9), 2006, p463 - 468 | en |
| dc.identifier.other | Y | en |
| dc.identifier.uri | http://hdl.handle.net/2262/5320 | |
| dc.description | PUBLISHED | en |
| dc.description.abstract | The remarkable success of the US 1983 Orphan Drug act might be replicated for small-firm patents by adopting its provision of a limited term during which the protection cannot be questioned. | en |
| dc.format.extent | 463 | en |
| dc.format.extent | 468 | en |
| dc.format.extent | 128215 bytes | |
| dc.format.mimetype | application/pdf | |
| dc.language.iso | en | en |
| dc.publisher | Sweet and Maxwell | en |
| dc.relation.ispartofseries | European Intellectual Property Review | en |
| dc.relation.ispartofseries | 28, (9), 2006 | en |
| dc.rights | Y | en |
| dc.subject | Patents | en |
| dc.subject | Small firms | en |
| dc.title | Limited Incontestability for Small-Firm Patents | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.rssinternalid | 40375 | |
